OpenURL Connection Search

Select item for more details and to access through your institution.

Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors.
Published in:
2013
By:
- Calcagno, A.;
- Tettoni, M. C.;
- Simiele, M.;
- Trentini, L.;
- Montrucchio, C.;
- D'Avolio, A.;
- Di Perri, G.;
- Bonora, S.
Publication type:
Letter
Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis.
Published in:
Journal of Antimicrobial Chemotherapy (JAC), 2011, v. 66, n. 1, p. 224, doi. 10.1093/jac/dkq385
By:
- Calcagno, A.;
- Baietto, L.;
- De Rosa, F. G.;
- Tettoni, M. C.;
- Libanore, V.;
- Bertucci, R.;
- D'Avolio, A.;
- Di Perri, G.
Publication type:
Article
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting.
Published in:
2010
By:
- Bonora, S.;
- Calcagno, A.;
- Viganò, O.;
- Bigliano, P.;
- Rusconi, S.;
- Trentini, L.;
- Tettoni, M. C.;
- Orofino, G.;
- Salassa, B.;
- Bramato, C.;
- D'Avolio, A.;
- Siccardi, M.;
- Colella, E.;
- Galli, M.;
- Di Perri, G.
Publication type:
Abstract
Diagnostic accuracy of new and old cognitive screening tools for HIV‐associated neurocognitive disorders.
Published in:
HIV Medicine, 2018, v. 19, n. 7, p. 455, doi. 10.1111/hiv.12622
By:
- Trunfio, M.;
- Vai, D.;
- Montrucchio, C.;
- Alcantarini, C.;
- Livelli, A.;
- Tettoni, M. C.;
- Orofino, G.;
- Audagnotto, S.;
- Imperiale, D.;
- Bonora, S.;
- Di Perri, G.;
- Calcagno, A.
Publication type:
Article
Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure.
Published in:
2017
By:
- Calcagno, A.;
- Pagani, N.;
- Ariaudo, A.;
- Arduino, G.;
- Carcieri, C.;
- D'Avolio, A.;
- Marinaro, L.;
- Tettoni, M. C.;
- Trentini, L.;
- Di Perri, G.;
- Bonora, S.
Publication type:
journal article

Found: 5

Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors.

Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis.

Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting.

Diagnostic accuracy of new and old cognitive screening tools for HIV‐associated neurocognitive disorders.

Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure.